CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth

Inclusion Criteria: * Subject must provide verbal informed consent for study participation prior to MTB case evaluation. * Tumor genetic profiling performed as standard of care must include ≥100 genes. * Tumor must contain at least one of the following genetic alterations: (A) an alteration known to be potentially associated with sensitization to a clinically available treatment. (the list of genetic alterations evolves as new information emerges and new drugs are developed); (B) an alteration suspected to be germline. * Subject must have ECOG Performance Status of 0 to 2. * Subject must have measurable or evaluable disease. * Subjects who have previously enrolled in this study can be enrolled a second time if they undergo genetic profiling of a tumor that was biopsied/sampled AFTER progression on an intervening line of treatment started after the time of first enrollment. Re-enrollment of such subjects must be noted in REDCap to facilitate longitudinal analysis. * Age ≥18 years. Exclusion Criteria: * Subjects with a tumor harboring a genetic alteration for which an FDA-approved drug is indicated that the patient has not yet received (example for exclusion: a melanoma with a BRAF-V600E mutation in a subject who has not yet been treated with a BRAF inhibitor). * Pregnant women.